Not everyone responds equally well to treatments for inflammatory bowel disease (IBD). What will work for individual patients ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, insights, and strategies to pursue value-driven solutions.

Not everyone responds equally well to treatments for inflammatory bowel disease (IBD). What will work for individual patients involves trial and error ...

The publication reviews the previously reported positive results from an open-label trial in which bexotegrast showed dose-dependent αvβ6 integrin receptor occupancy in lungs of patients with IPF.

Alterations in AM function following the exposure to berry-flavored e-cigarettes that lead to poor immune responses to pathogens and reduced host survival.

Presented New CRB-913 Pre-Clinical Data at Obesity Week 2024 - Phase 1 Trial Expected to Commence in Q1 2025 ...

Results from a retrospective cohort study show lower all-cause mortality and fewer hospitalizations and intestinal ...

Researchers have uncovered new targets that could be the key to effectively treating glioblastoma, a lethal type of brain cancer. These targets were identified through a screen for genetic ...

The webcast replay will be archived on the Pliant website for 30 days following the conclusion of the event. About Pliant Therapeutics, Inc. Pliant Therapeutics is a late-stage biopharmaceutical ...

Skeletal stem cells have been isolated from various tissues, including periosteum and bone marrow, where they exhibit key functions in bone biology and hematopoiesis, respectively. The role of ...

Researchers have identified potential drug targets in glioblastoma cancer stem cells, providing a new approach to treat this ...

CRB-913 demonstrated a wide dose response weight loss curve in DIO mice ranging from 5 mg/kg/day to 80 mg/kg/day with no plateauing effect and reaching a weight loss of 31% by day 19. Extending the ...